Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.905 -0.115 (-1.64%)

Streaming Delayed Price Updated: 12:06 PM EST, Mar 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

31 32 Next >

Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday ↗

November 15, 2024

Via Benzinga

Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS ↗

November 15, 2024

President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

Via Investor's Business Daily

Topics Government

FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment ↗

November 14, 2024

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory hurdles.

Via Benzinga

AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care? ↗

November 13, 2024

AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care.

Via Benzinga

Topics Artificial Intelligence

Top 3 Health Care Stocks You'll Regret Missing In November ↗

November 05, 2024

Via Benzinga

Uncovering Potential: Compass Pathways's Earnings Preview ↗

October 30, 2024

Via Benzinga

Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript ↗

October 31, 2024

CMPS earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results ↗

October 31, 2024

Via Benzinga

As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash ↗

October 31, 2024

Compass Pathways delays key Phase 3 psilocybin trial readouts, triggering a 30% workforce reduction amid efforts to conserve cash and refocus.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 31, 2024

Via Benzinga

Crude Oil Gains 1%; Meta Shares Fall Following Q3 Results ↗

October 31, 2024

Via Benzinga

Estée Lauder, Robinhood, eBay And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

October 31, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 31, 2024

Via Benzinga

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

October 31, 2024

From Compass Pathways plc

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 25, 2024

Via Benzinga

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

October 24, 2024

From Compass Pathways plc

Via Business Wire

Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes ↗

October 07, 2024

Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential.

Via Benzinga

Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder ↗

September 26, 2024

New study suggests psilocybin may help treat body dysmorphic disorder by rewiring brain connectivity and reducing obsessive thought patterns.

Via Benzinga

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

September 23, 2024

From Compass Pathfinder Limited

Via Business Wire

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗

September 15, 2024

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Via Talk Markets

MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward? ↗

September 12, 2024

Via Benzinga

Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗

September 10, 2024

While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are...

Via Talk Markets

Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August ↗

September 06, 2024

The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a...

Via Talk Markets

Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down ↗

September 05, 2024

Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy.

Via Benzinga

Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration ↗

September 05, 2024

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.

Via Benzinga

Topics Artificial Intelligence

Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday ↗

August 26, 2024

Via Benzinga

Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week ↗

August 24, 2024

Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past...

Via Talk Markets

Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD ↗

August 15, 2024

This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest...

Via Talk Markets

Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript ↗

August 01, 2024

CMPS earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗

July 31, 2024

Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.